Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 7:6:30.
doi: 10.4103/2277-9175.201687. eCollection 2017.

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma

Valiollah Mehrzad  1 , Farzaneh Ashrafi  1 , Ali Reza Farrashi  2 , Reyhaneh Pourmarjani  3 , Mehdi Dehghani  4 , Armindokht Shahsanaei  5
Affiliations

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma

Valiollah Mehrzad et al. Adv Biomed Res. .

Abstract

Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients. The treatment of choice for these patients is high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). Response to salvage chemotherapy (SCT) partial remission (PR) is necessary before HDCT with ASCT. However, its applicability is restricted mostly to patients responding to salvage chemotherapy. Optimal salvage regimen for these patients is unclear. In this study, our aim was to compare the efficacy profiles of ifosfamide, carboplatin, and etoposide (ICE) and etoposide-steroid-cytarabine-cisplatin (ESHAP) (cytosine arabinoside, cisplatin, and dexamethasone) regimens in the salvage treatment of relapsed or refractory HD.

Materials and methods: In this retrospective analysis, 114 patients with primary refractory or relapsed HD who received ICE or ESHAP salvage regimen were included.

Results: Of 114 patients, 47 (41.2%) were females and the median age was 31.5 years. Response could be evaluated in 114 patients. Of 114 patients, 38 (33%) achieved complete remission (CR) and 21 (18.4%) achieved PR, leading to an overall response rate (ORR: CR + PR) of 51.4%. In the evaluable ICE group (n = 41), rates of CR, PR, and ORR were 21.9%, 17.1%, and 39% and in the ESHAP group (n = 73), rates of CR, PR, and ORR were 39.7%, 19.2%, and 58.9% (for ORR, P = 0.04), respectively.

Conclusion: In patients with relapsed or refractory HD, treatment with ESHAP seems to have higher rates of response than ICE regimen does.

Keywords: Carboplatin; Hodgkin's lymphoma; etoposide; etoposide-steroid-cytarabine-cisplatin; ifosfamide; refractory; relapse.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Longo D. Malignancies of lymphoid cells. In: Fauci A, Kasper D, Longo D, Braunwald E, Hauser S, Jameson J, et al., editors. Harrison's internal medicine. 17th ed. New York: Mc Graw-Hill Companies; 2008. pp. 698–9.
    1. Lacy J, Seropian S. Disorders of lymphocytes. In: Carpenter CH, Griggs R, Loscalzo J, editors. Cecil essentials of medicine. 6th ed. Philadelphia: WB Saunders Company; 2004. pp. 472–4.
    1. DeVita VT., Jr A selective history of the therapy of Hodgkin's disease. Br J Haematol. 2003;122:718–27. - PubMed
    1. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest. 2008;26:401–6. - PubMed
    1. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van’t Veer MB, Lybeert ML, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003;348:2396–406. - PubMed